UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.

IF 1.9 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pharmacogenomics Pub Date : 2023-06-01 DOI:10.2217/pgs-2023-0096
Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron Hj Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J Swen
{"title":"<i>UGT1A1</i> genotype-guided dosing of irinotecan: time to prioritize patient safety.","authors":"Sofía Lj Peeters,&nbsp;Maarten J Deenen,&nbsp;Anna Mj Thijs,&nbsp;Emma C Hulshof,&nbsp;Ron Hj Mathijssen,&nbsp;Hans Gelderblom,&nbsp;Henk-Jan Guchelaar,&nbsp;Jesse J Swen","doi":"10.2217/pgs-2023-0096","DOIUrl":null,"url":null,"abstract":"<p><p>Tweetable abstract Pretreatment <i>UGT1A1</i> genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of <i>UGT1A1</i> genotype-guided irinotecan dosing in routine oncology care.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"24 8","pages":"435-439"},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0096","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
UGT1A1基因型引导的伊立替康给药:优先考虑患者安全的时间
预处理UGT1A1基因分型和70%伊立替康剂量强度对代谢不良的癌症患者是安全、可行、划算的,也是伊立替康安全治疗的必要条件。现在是更新指南的时候了,以便在常规肿瘤治疗中迅速实施UGT1A1基因型指导的伊立替康给药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacogenomics
Pharmacogenomics 医学-药学
CiteScore
3.40
自引率
9.50%
发文量
88
审稿时长
4-8 weeks
期刊介绍: Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
期刊最新文献
Advancing pharmacogenomics research: automated extraction of insights from PubMed using SpaCy NLP framework. Effect of UGT1A6 and UGT2B7 polymorphisms on the valproic acid serum concentration and drug-induced liver injury. Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study. PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typing.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1